Skip to main content
. 2023 Jan 19;13(6):2715–2735. doi: 10.1016/j.apsb.2023.01.014

Figure 8.

Figure 8

D10 and D15 significantly repressed EBC-1 tumor growth in vivo by i.p. administration. (A) Treatment schedule for the EBC-1 xenograft tumors model treated with vehicle control, tepotinib (10 mg/kg), D10 (10 mg/kg) or D15 (10 mg/kg). (B) The change of tumor volume was measured every 2 days. (C) Tumors' picture. (D) Tumor weight of all mice in each group (n = 6). Data are mean ± SD, ns (no significance), ∗∗P < 0.01 (one-way ANOVA). (E) The change of body weight of all mice was measured every 2 days.